Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Griseofulvin Action Pathway
Homo sapiens
Drug Action Pathway
Griseofulvin is an antifungal agent used to treat ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi. Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi.
Following oral administration, griseofulvin is deposited in the keratin precursor cells. It also has a greater affinity for diseased tissue. It binds to the new keratin which becomes resistant to fungal invasion. The exact mechanism by which Griseofulvin inhibits fungal cell growth is not clear, but it is thought to inhibit fungal cell mitosis and nuclear acid synthesis. At the action site, it binds to fungal tubulin at the beta site. This alters the fungal process of mitosis, likely inhibiting mytosis and preventing further growth of fungal cells.
References
Griseofulvin Pathway References
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. doi: 10.1038/nrd2199.
Pubmed: 17139284
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. doi: 10.1038/nrd2132.
Pubmed: 17016423
Czymmek KJ, Bourett TM, Shao Y, DeZwaan TM, Sweigard JA, Howard RJ: Live-cell imaging of tubulin in the filamentous fungus Magnaporthe grisea treated with anti-microtubule and anti-microfilament agents. Protoplasma. 2005 Apr;225(1-2):23-32. doi: 10.1007/s00709-004-0081-3. Epub 2005 May 4.
Pubmed: 15868210
Kiso T, Fujita K, Ping X, Tanaka T, Taniguchi M: Screening for microtubule-disrupting antifungal agents by using a mitotic-arrest mutant of Aspergillus nidulans and novel action of phenylalanine derivatives accompanying tubulin loss. Antimicrob Agents Chemother. 2004 May;48(5):1739-48. doi: 10.1128/AAC.48.5.1739-1748.2004.
Pubmed: 15105129
FDA Approved Drug Products: Gris-Peg (ultramicrosize griseofulvin) tablets for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050475s057lbl.pdf
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings